Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Wilson
Lance D
LD
Tsai
Chia-Ti
CT
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000209:etiology*; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D015153:Blotting, Western; D004195:Disease Models, Animal; D022062:Electrophysiologic Techniques, Cardiac; D005355:Fibrosis / Q000188:drug therapy / Q000209:etiology; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D000077205:Pioglitazone; D011817:Rabbits; D013777:Tetrazoles / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology*
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007004:Hypoglycemic Agents; D013777:Tetrazoles; D045162:Thiazolidinediones; C081643:candesartan; D000077205:Pioglitazone